Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2015

View Archived Issues

Medimmune begins phase I study of MEDI-1873 in solid tumors

BioAtla enters into strategic license and option agreement with Pfizer

Novel optimized human FVIII vector SPK-8005 demonstrates therapeutic utility in hemophilia

Takeda and Cour form celiac disease immunomodulator collaboration

Novartis starts phase III trial of indacaterol/glycopyrronium/mometasone in asthma

FACIT gains rights to WDR5 inhibitors for mixed lineage leukemia

First patient dosed in phase I/II study of NKTR-214

DBV initiates pivotal study of Viaskin Peanut in children

Biocept and Baylor College of Medicine to develop liquid biopsy test for estrogen receptor mutations

Lilly starts phase I trial of MCI candidate LY-2599666

Roche divulges TAAR1 ligands

Novartis initiates first-in-human trial of LNA-043

Vaxart tests influenza vaccine VXA-BYW.10 in healthy adults

Morphotek reports phase I data from MORAb-022-001 trial

Fluorescent tumor imaging achieved with BLZ-100 in phase I glioma trial

FDA advisory committee recommends approval of reslizumab

Gates Foundation funds research for a tapeworm vaccine

Bayer Schering Pharma reports MNK1 inhibitors

Wyss Institute to develop combined diagnostic and epinephrine injector device for anaphylaxis

Biocad's biosimilar bevacizumab approved in Russia

FDA decides to review Anika's Cingal as drug rather than device

Cancer Research Technology and AstraZeneca disclose glutaminase inhibitors

Fuji Chemical Industry develops carotenoid derivatives

Epizyme discovers first orally bioavailable SMYD3 inhibitor EPZ-031686

First-in-class CDK7 inhibitor SY-351 demonstrates efficacy in AML

Several collaborations announced in cancer immunotherapy and other related areas

Achillion's oral, small-molecule reversible factor D inhibitors for PNH and aHUS

ARMGO's ARM-210 receives FDA orphan drug and rare pediatric disease designation for DMD

FDA grants fast track to NuSirt's NS-0200 for NAFLD and NASH

TEI-SARM2 shows promise for the treatment of muscle wasting diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...